Immunovant
IMVT
IMVT
180 hedge funds and large institutions have $2.24B invested in Immunovant in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 74 increasing their positions, 63 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
2.58% more ownership
Funds ownership: 51.14% → 53.72% (+2.6%)
9% less funds holding
Funds holding: 197 → 180 (-17)
47% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 36
Holders
180
Holding in Top 10
7
Calls
$71.2M
Puts
$21.8M
Top Buyers
| 1 | +$58.6M | |
| 2 | +$48.6M | |
| 3 | +$41.7M | |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$32.6M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$21.7M |
Top Sellers
| 1 | -$23.1M | |
| 2 | -$19.8M | |
| 3 | -$18.4M | |
| 4 |
FAM
Fred Alger Management
New York
|
-$16M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$11.6M |